The use of databases for quality assessment in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 25, Issue 6 SUPPL. 47, 2007, Pages

  Stamm, Tanja A ^a   Aletaha, Daniel ^a   Pflugbeil, Stephan ^b   Kapral, Theresa ^a   Montag, Karin ^b   Machold, Klaus P ^a   Smolen, Josef S ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital   (Austria)

Author keywords

Clinical disease activity index (CDAI); Quality assessment; Rheumatoid arthritis

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; CLINICAL PRACTICE; DISEASE ACTIVITY; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; MEDICAL RESEARCH; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY CONTROL; REFERENCE DATABASE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; DATABASES AS TOPIC; ELECTRONICS, MEDICAL; HUMANS; QUALITY ASSURANCE, HEALTH CARE; SOFTWARE;

EID: 36448970927     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. CHOI HK, HERNAN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 2002; 359: 1173-7.
2. WOLFE F, SHARP JT: Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression. Arthritis Rheum 1998; 41: 1571-82.
3. DROSSAERS-BAKKER KW, DE BUCK M, VAN ZEBEN D, ZWINDERMANN AH, BREEDVELD FC, HAZES M: Long-term course and outcome of functional capacity in rheumatoid arthritis: The effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42: 1854-60.
4. WELSING PM, VAN GESTEL AM, SWINKELS HL, KIEMENEY LA, VAN RIEL PL: The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009-17.
5. VAN LEEUWEN MA, VAN RIJSWIJK MH, SLUITER WJ et al.: Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997; 24: 20-7.
6. ALETAHA D, NELL VP, STAMM T et al.: Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-R806.
7. MALLYA RK, DE BEER FC, BERRY H, HAMILTON ED, MACE BE, PEPYS MB: Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982; 9: 224-8.
8. PINCUS T, BROOKS RH, CALLAHAN LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 26-34.
9. SCOTT DL, GRINDULIS KA, STRUTHERS GR, COULTON BL, POPERT AJ, BACON BA: Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 8-17.
10. SMOLEN JS, ALETAHA D: The challenge of following process, damage and function of RA patients in clinical care. Curr Rheumatol Rep 2003; 5: 336-40.
11. WOLFE F, HAWLEY DJ, CATHEY MA: Clinical and health status measures over time: Prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991; 18: 1290-7.
12. SMOLEN JS, VAN DER HEIDE DM, ST CLAIRE W et al.: Predictors of joint damage in patients with early rheumatoid arthritis treated with high dose methotrexate with or without concomitant infliximab. Arthritis Rheum 2006; 54: 702-10.
13. SCOTT DL, PUGNER K, KAARELA K et al.: The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 122-32.
14. ALETAHA D, SMOLEN J, WARD MM: Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784-92.
15. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
16. GOEKOOP-RUITERMAN YP, VRIES-BOUWSTRA JK, ALLAART CF A et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
17. FRANSEN J, MOENS HB, SPEYER I, VAN RIEL PL: Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: A multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64: 1294-8.
18. ANTONI C, MAINI RM, GRUNKE M et al.: Cooperative on quality of life in rheumatic diseases: Results of a survey among 6000 patients across 11 European countries. Arthritis Rheum 2002; 46 (Suppl.).
19. DROSOS AA, LANCHBURY JS, PANAYI GS, MOUTSOPOULOS HM: Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum 1992; 35: 745-8.
20. SMOLEN JS, SOKKA T, PINCUS T, BREEDVELD FC: A proposed treatment algorithm for rheumatoid arthritis: Aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S209-S210.
21. MIERAU M, SCHOELS M, GONDA G, FUCHS J, ALETAHA D, SMOLEN JS: Assessing remission in clinical practice. Rheumatology (Oxford) 2007; 46: 975-9.
22. FELSON DT, ANDERSON JJ, BOERS M: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis in clinical trials. Arthritis Rheum 1993; 36: 729-40.
23. VAN GESTEL AM, VAN RIEL P: Evaluation of early rheumatoid arthritis disease activity and outcome. Ballieres Clin Rheumatol 1997; 11: 63.
24. VAN RIEL PL, VAN GESTEL AM, VAN DE PUTTE LB: Development and validation of response criteria in rheumatoid arthritis: Steps towards an international consensus on prognostic markers. Br J Rheumatol 2004; 35 (Suppl. 2): 4-7.
25. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis [see comments]. Arthritis Rheum 1995; 38: 727-35.
26. VAN GESTEL AM, PREVOO ML, 'T HOF MA, VAN RIJSWIJK M, VAN DE PUTTE LB, VAN RIEL P: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and World Health Organizaton/International League Against Rheumatism Criteria. Arthritis Rheum 1996: 39: 34-40.
27. VAN DER HEIJDE DM, 'T HOF MA, VAN RIEL P, THEUNISSE LA, LUBBERTS EW, LEEUWEN MA: Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score. Ann Rheum Dis 1990; 31: 219-20.
28. PREVOO ML, 'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis [see comments]. Arthritis Rheum 1995; 38: 44-8.
29. VAN GESTEL AM, ANDERSON JJ, VAN RIEL P, BOERS M, HAAGSMA CJ, RICH B: ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999; 26: 705-11.
30. SMOLEN JS, BREEDVELD FC, SCHIFF MM et al.: A simplified disease activity index for rheumatoid arthritis for use in clinical trials. Rheumatology 2003; 42: 1-14.
31. SMOLEN JS: The work of the EULAR Standing Committee on International Clnical Studies Including Therapeutic Trials (ESCISIT). Br J Rheumatol 1992; 31: 219-20.
32. BOERS M, TUGWELL P, BROOKS PM: Progress towards optimal end-points in rheumatoid arthritis. Bio Drugs 1997; 7: 40-50.
33. GOLDSMITH C, BOERS M, BOMBARDIER C, TUGWELL P: Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. J Rheumatol 1993; 20: 561-5.
34. VAN DER HEIJDE DM, VAN'T HOF MA, VAN RIEL PL, VAN LEEUWEN MA, VAN RIJSWIJK MH, VAN DE PUTTE LB: Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992; 51: 177-81.
35. WARD MM, JAVITZ HS, YELIN EH: The direct cost of rheumatoid arthritis. Value Health 2000; 3: 243-52.
36. BANSBACK NJ, BRENNAN A, GHATNEKAR O: Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005; 64: 995-1002.
37. HAAN CK, ADAMS M, COOK R: Improving the quality of data in your database: Lessons from a cardiovascular center. Jt Comm J Qual Saf 2004; 30: 681-8.
38. MEISSNER W, ULLRICH K, ZWACKA S: Benchmarking as a tool of continuous quality improvement in post-operative pain management. Eur J Anaesthesiol 2006; 23: 142-8.
39. MAUNE S, SCHMIDT C, KUCHLER T: [Measurement of the outcome quality as beginning of total quality management in otorhinolaryngology]. Laryngorhinnotologie 2001; 80: 101-8.
40. SAINFORT F, RAMSAY JD, FERREIRA PL, MEZGHANI L: A first step in total quality management of nursing facility care: Development of an empirical causal model of structure, process and outcome dimensions. Am J Med Qual 1994; 9: 74-86.
41. VINCENT C, MOORTHY K, SARKER SK, CHANG A, DARZI AW: Systems approaches to surgical quality and safety: From concept to measurement. Ann Surg 2004; 239: 475-82.
42. DHINGRA H, LASKI ME: Outcomes research in dialysis. Semin Nephrol 2003; 23: 295-305.
43. THE METEOR FOUNDATION: METEOR (Measurement of Efficacy of Treatment in the 'Era of Outcome' in Rheumatology) http://www.meteorfoundation.com/. 2007. 30-6-2007.
44. KAHN KL, MACLEAN CH, LIU H et al.: Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice. Arthritis Rheum 2006; 55: 884-91.
45. KAHN KL, MACLEAN CH, WONG AL et al.: Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort. Arthritis Rheum 2007; 57: 707-15.